title: Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma.
authors.affiliation: Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC. Electronic address: hector.g.ortega@gsk.com.
authors.forename: Hector
authors.initials: H
authors.lastname: Ortega
authors.affiliation: Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC.
authors.forename: Lynn
authors.initials: L
authors.lastname: Katz
authors.affiliation: Clinical Statistics, GlaxoSmithKline, Stockley Park, United Kingdom.
authors.forename: Necdet
authors.initials: N
authors.lastname: Gunsoy
authors.affiliation: Clinical Statistics, GlaxoSmithKline, Stockley Park, United Kingdom.
authors.forename: Oliver
authors.initials: O
authors.lastname: Keene
authors.affiliation: Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC.
authors.forename: Steven
authors.initials: S
authors.lastname: Yancey
mesh_terms: D001249:Asthma / Q000175:diagnosis* / Q000473:pathology*; D004802:Eosinophilia / Q000175:diagnosis* / Q000473:pathology*; D004804:Eosinophils / Q000473:pathology*; D006801:Humans